Diabetic equipment manufacturer Ypsomed Holding AG (YPSN.SW,YPHDF) Monday said that it expects sales between 0.9 billion Swiss francs and 1.1 billion francs and EBIT in the range of 280 million francs and 340 million francs by financial year 2029/30. The company added that it plans to sustain a Return on Capital Employed or ROCE of around 20 percent during the period.
Ypsomed Holdings said that it is now in a strong financial position, helped by proceeds from the sale of its Diabetes Care business. Free cash flow is expected to improve and turn positive within the next three years, it added.
The company said that in the coming years, it will keep on investing in capacity expansion, research and development, even while maintaining its dividend policy.
According to Ypsomed Holdings, details regarding its US expansion plans will released in October.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.